Stellaromics, a Boston, MA-based provider of in situ spatial multi-omics technology, raised $25m in Series A financing round.
Backers included Plaisance Capital Management and a private family office based in Silicon Valley.
The company intends to use the funds to consolidate the business and establish a new headquarters to house its growing team of innovators. They will continue to focus on advancing the development of its revolutionary Plexa™ products; the alpha version is expected to be available via a Technology Access Program in early 2024.
In tandem with the fundraise, Stellaromics has appointed Todd Dickinson, Ph.D., as President & CEO. In addition, Ye Fu, Ph.D., has been appointed as CTO.
Founded in 2022 by Karl Deisseroth, M.D., Ph.D., and Xiao Wang, Ph.D. , Stellaromics is developing spatial technology that aims to accelerate the development of fundamentally novel drug treatments, including for autoimmune diseases, cancer, neuropsychiatric disorders, and infectious diseases. Its flagship product, STARmap (Spatially-resolved Transcript Amplicon Readout mapping), reveals gene expression patterns within intact tissue, aiding in the identification of treatment targets and supporting biomedical research. Stellaromics is in late-stage product development on its Plexa™ suite of products, designed to enable researchers and clinicians to create detailed cellular maps for enhanced disease understanding.
FinSMEs
02/11/2023